The estimated Net Worth of John Purpura is at least $1.1 Million dollars as of 13 October 2023. Mr. Purpura owns over 14,505 units of Delcath Systems stock worth over $413,599 and over the last 14 years he sold DCTH stock worth over $0. In addition, he makes $682,541 as Chief Operating Officer and Executive Vice President - Global Head of Operations at Delcath Systems.
Sign up
Mr. Purpura DCTH stock SEC Form 4 insiders trading
John has made over 7 trades of the Delcath Systems stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 14,505 units of DCTH stock worth $49,897 on 13 October 2023.
The largest trade he's ever made was buying 14,505 units of Delcath Systems stock on 13 October 2023 worth over $49,897. On average, John trades about 1,556 units every 166 days since 2011. As of 13 October 2023 he still owns at least 41,526 units of Delcath Systems stock.
You can see the complete history of Mr. Purpura stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Purpura biography
John Purpura serves as Chief Operating Officer, Executive Vice President - Global Head of Operations of the Company. He joined the Company as Executive Vice President, Regulatory Affairs and Quality Assurance in November 2009 and was promoted to Executive Vice President, Global Head of Operations on July 19, 2016. Prior to joining the Company, he was with Bracco Diagnostics (formerly E-Z-EM,Inc.) as Vice President and then Executive Director of International Regulatory Affairs from 2007 to 2008 and Head of Regulatory Affairs for North America and Latin America from 2008 to 2009. Prior to E-Z-EM, Inc., Mr. Purpura had an 11-year career with Sanofi-Aventis, ultimately serving as Associate Vice President for Regulatory CMC from 2005 to 2007. From 1985 to 1995, he had various quality and regulatory management roles with Bolar Pharmaceuticals, Luitpold Pharmaceuticals and Eon Labs Manufacturing. He earned his M.S. in Management & Policy and B.S. degrees in Chemistry and Biology at the State University of New York at Stony Brook.
What is the salary of John Purpura?
As the Chief Operating Officer and Executive Vice President - Global Head of Operations of Delcath Systems, the total compensation of John Purpura at Delcath Systems is $682,541. There are no executives at Delcath Systems getting paid more.
How old is John Purpura?
John Purpura is 59, he's been the Chief Operating Officer and Executive Vice President - Global Head of Operations of Delcath Systems since 2020. There are 3 older and 6 younger executives at Delcath Systems. The oldest executive at Delcath Systems, Inc. is Roger Stoll, 78, who is the Non-Executive Independent Chairman of the Board.
What's John Purpura's mailing address?
John's mailing address filed with the SEC is C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK, NY, 10019.
Insiders trading at Delcath Systems
Over the last 5 years, insiders at Delcath Systems have traded over $0 worth of Delcath Systems stock and bought 1,192,084 units worth $8,856,388 . The most active insiders traders include Marco Taglietti, Gerard J Michel, and Advisors, Inc. Rosalind. On average, Delcath Systems executives and independent directors trade stock every 25 days with the average trade being worth of $242,307. The most recent stock trade was executed by Gil Aharon on 19 March 2024, trading 26,882 units of DCTH stock currently worth $100,001.
What does Delcath Systems do?
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO includes the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma; and the ALIGN trial, a Phase 3 clinical trial for intrahepatic cholangiocarcinoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
What does Delcath Systems's logo look like?
Complete history of Mr. Purpura stock trades at Delcath Systems
Delcath Systems executives and stock owners
Delcath Systems executives and other stock owners filed with the SEC include:
-
John Purpura,
Chief Operating Officer, Executive Vice President - Global Head of Operations -
John Purpura M.S.,
Chief Operating Officer -
Gerard J. Michel,
CEO & Director -
Roger Stoll,
Non-Executive Independent Chairman of the Board -
John Sylvester,
Independent Director -
Steven Salamon,
Independent Director -
Elizabeth Czerepak,
Independent Director -
Gilad Aharon,
Independent Director -
Christine Padula,
Interim Principal Accounting Officer -
Gerard Michel,
Chief Executive Officer, Director -
Dr. Johnny John M.D.,
Sr. VP Clinical Devel. & Medical Affairs -
Robin Wagge,
Sr. VP of Rubenstein Associates -
Thomas Johnson,
Sr. Director of Corp. Communications -
Bridget A Martell,
-
Gil Aharon,
-
Advisors, Inc. Rosalind,
Director -
Anthony Dias,
VP FINANCE -
Advisors, Inc.Aharon Gil Sa...,
-
Johnny John,
SVP CLINICAL DEV & MED AFFAIRS -
Jennifer K. Simpson,
President and CEO -
William Dodge Rueckert,
Director -
Marco Taglietti,
Director -
Barbra Keck,
Chief Financial Officer -
Advisors, Inc.Salamon Steve...,
-
Martha S. Rook,
CHIEF OPERATING OFFICER -
Vojo Vukovic,
CHIEF MEDICAL OFFICER -
Kevin Muir,
GM INTERVENTIONAL ONCOLOGY -
David L. Hoffman,
GEN'L COUNSEL, CCO & SECY